Pipeline Report: Several blockbuster drugs are poised to go

Therapies in the oncology, neurology and autoimmune disease pipelines could soon pose challenges to existing standards of care.

Related Keywords

Japan , Novarti Xolair , Sanofi Dupixent , Alnylam Onpattro , Abbvie Rinvoq , Lavan Khandan , Eli Lilly , Alessandra Franceschetti , Scott Morano , Alexion Soliris , Abbvie Skyrizi , Bristol Myers Squibb , Elizabeth Baynton , Eric Blouin , Iovance Biotherapeutics , Adam Schaffner , Amanda Weyerbacher , Lilly Olumiant , Michele Godby Drennen , Julie Hoggatt , Astrazeneca Amgen , Astrazeneca Alexion , Nicole Allie , Talin Sesetyan , Hannah Brown , Amgen Otezla , Peter Collins , Amgen , Drug Administration , Credit Suisse , Novartis , Pfizer , Alnylam Pharmaceuticals , Inthought Research , Astrazeneca , Johnson , Myers Squibb , Alexion Pharmaceutical , Bluebird Bio , Thought Research , Ipsos Healthcare , Leo Pharma , For Psa , Penny Robinson , Legend Biotech , Leon Henderson Maclennan , Lynda Levy , Topline Phase , Aine Kyle ,